Business Context and Reporting Period
This Form 8-K filing by Personalis, Inc. (PSNL) reports a material event occurring on May 19, 2026. The company, incorporated in Delaware and headquartered in Fremont, California, operates in the molecular diagnostics sector.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory coverage expansion event rather than financial performance data.
Material Changes
On May 19, 2026, the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program expanded Medicare coverage for Personalis's ultrasensitive NeXT Personal test. The expansion specifically includes monitoring treatment response to neoadjuvant therapy (NAT) for patients diagnosed with:
- Stage II-III Triple-Negative Breast Cancer (TNBC)
- HER2-positive (HER2+) breast cancer
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the announcement of the coverage expansion. No unusual items were reported.
Investor Verification Checklist
- Verify the specific CPT codes or billing requirements associated with the new Medicare coverage for neoadjuvant therapy monitoring.
- Assess the potential revenue impact of the expanded coverage for TNBC and HER2+ breast cancer patients.
- Confirm if similar coverage expansions are pending for other cancer types or treatment stages.
- Review the company's recent 10-K or 10-Q filings for baseline financial data not included in this 8-K.